CycloSyn Therapeutics — Organelle-Targeted Drug Delivery
RUO & Pre-Clinical · V4 Platform Ready

Drug delivery, solved
at the organelle level.

CycloSyn pioneers β-cyclodextrin polymer nanoplatforms that deliver therapeutics precisely inside cells — targeting the exact organelle where disease originates.

Partner With Us → See the Platform
2.3×
ATP Output Increase
57%
Plaque Regression (2025)
5+
Formulas · One Platform
$820M+
Platform Valuation Model

The Problem

Current drug delivery fails at the subcellular level.

80% of drug candidates fail not because they don't work — but because they can't reach the right place inside the cell.

🎯
No Organelle Specificity
LNPs and traditional nanoparticles deliver to the cell membrane — not the mitochondria, nucleus, or lysosomes where disease actually originates.
⚡
Low Bioavailability
Active payloads degrade before reaching disease sites, drastically reducing therapeutic effect at the intended cellular target.
🔒
Single-Purpose Platforms
Existing delivery systems are designed for one indication. Repurposing requires a full rebuild — costing years and hundreds of millions.

CycloSyn Cascade Architecture™ V4

A modular, four-layer platform engineered for precision.

Each layer is independently programmable. Swap the targeting element and the entire system redirects — without rebuilding the platform.

LAYER 01 +
β-CDP Core
Epichlorohydrin-cross-linked β-cyclodextrin polymer matrix. High-capacity payload encapsulation. Patent-protected composition and architecture.
Particle size: 60–80 nm · PDI <0.18 · Yield ≥70% · Drug loading efficiency >85% · Biocompatible polymer backbone with no known immunogenicity at therapeutic concentrations.
LAYER 02 +
PBAE Stealth/XR Shell
pH-responsive poly(β-amino ester) interface. Activates at acidic pH ~6.0 inside target organelles — silent in healthy tissue at pH 7.4.
Zeta potential shifts from neutral at pH 7.4 → +20–30mV at pH 6.0, confirming PBAE switching. Release ratio ≥5× at disease pH vs. physiological pH. Patent Claim 34.
LAYER 03 +
HA Targeting Layer
Medium-MW hyaluronic acid (200–300 kDa) binds CD44 receptors on diseased tissue. Anti-inflammatory M2 macrophage promotion in circulation.
Post-coating size: 100–150 nm · Zeta -10 to -20mV confirming successful HA deposition · CD44 overexpressed 3–10× on cancer cells, inflamed tissue, and macrophages — giving the platform inherent tissue selectivity.
LAYER 04 +
PC:SM Lipid Shell
DPPC:Sphingomyelin 70:30 molar ratio. Provides biocompatible stealth, membrane interplay, and fusion-ready framing for cellular entry.
70:30 PC:SM molar ratio is patent-critical specification (Patent Claim 4). Sphingomyelin content modulates membrane fluidity for optimal endosomal escape. Provides immune evasion in circulation — extending plasma half-life.
1
BloodstreamPC:SM shell provides stealth
Lipid outer coat mimics cell membranes, evading immune recognition during systemic circulation.
2
HA TargetingBinds CD44 receptors
Hyaluronic acid layer locks onto CD44 receptors, which are 3–10× overexpressed on diseased cells.
3
Cell UptakeReceptor-mediated endocytosis
CD44 binding triggers active uptake into the cell via receptor-mediated endocytosis — not passive diffusion.
4
AcidificationpH drops to ~6.0
As the endosome matures, its internal pH drops from 7.4 to ~6.0 — activating the PBAE shell.
5
PBAE ActivatesShell opens, payload freed
At pH ~6.0, the PBAE coating protonates, destabilizes, and releases the therapeutic payload with precision.
6
Organelle DeliveryPrecise intracellular targeting
Cell-penetrating peptides and organelle-targeting sequences direct the freed payload to mitochondria, nucleus, or lysosome.

Proof of Concept

Validated results. Published data.

Campaign 1 complete — full 5-gate validation protocol passed for V4.5 MitoRepair. All data captured in pharma-grade Master Batch Records.

Hover each card to see detail

2.3×
ATP Output Increase
V4.5 MitoRepair · Gate 5 validated
What this meansCells treated with V4.5 MitoRepair produced 2.3× more ATP than the dysfunction control — demonstrating functional energy rescue at the mitochondrial level.
2.1×
ROS Reduction
Oxidative stress reversal · n=3 experiments
What this meansReactive oxygen species — a key driver of cellular aging and metabolic disease — reduced by 2.1× in treated cells. Independently replicated three times.
57%
Plaque Regression
2025 published study · ApoE⁻/⁻ murine model
Published 2025Using the exact CycloSyn β-CDP + Ferulic Acid architecture, a peer-reviewed study showed 57% atherosclerotic plaque regression in the gold-standard ApoE knockout mouse model.
5×+
Cellular Uptake Ratio
pH-selective · Gate 4 validated
Smart selectivityThe platform takes up 5× more payload at acidic pH 6.5 (disease environment) than neutral pH 7.4 (healthy tissue) — confirming the platform is selectively active only where it's needed.
5-Gate Validation Protocol V4.5 MitoRepair — Campaign 1 Complete ✓
Gate 1
Polymer Synthesis
✓
Gate 2
pH-Response
✓
Gate 3
Lipid Coating
✓
Gate 4
Cell Uptake
✓
Gate 5
Functional Rescue
✓

Pipeline

Four formulations. One platform chassis.

Same β-CDP core. Swap the payload. New indication. No platform rebuild required.

Formulation Indication Target Organelle Stage
V4.5 MitoRepair Mitochondrial disease, metabolic disorders, neurodegeneration Mitochondria Validated
Formula X Cardiovascular — atherosclerosis, plaque regression Endosome / Cytoplasm Active RUO
V4-N1 NeuroRescue Neurodegeneration — Parkinson's, ALS (BBB-crossing) Nucleus / BBB Expansion
V4-C1 Senolytic Cellular senescence, aging-related disease Lysosome Expansion
Exo-Hybrid Series β-CDP × Exosome hybrids — cell-to-cell molecular communication Multi-organelle RUO

Market Context

Pharma pays platform premiums. No clinical trials required.

Platform delivery technology commands strategic premiums. Acquirers pay for IP breadth and reproducibility — not clinical data alone.

Acuitas Therapeutics
LNP Delivery Platform
$400M+
Licensed to Moderna & Pfizer — zero clinical data at exit
Translate Bio
LNP / mRNA Delivery
$3.2B
Acquired by Sanofi · Phase 1/2 only at time of deal
Alnylam (2004 IPO)
siRNA Delivery
$300M
Platform only — no approved products at exit

CycloSyn Therapeutics

Multi-organelle β-CDP platform · 5 formulas · Patent portfolio · Pharma-grade documentation

$820M – $1.19B
Modeled platform valuation

The Team

Built for execution and acquisition.

Operating from NEOMED REDIzone Biotech Incubator — a credentialed life sciences research facility in Rootstown, Ohio.

JF
Jason Fallow
Founder & CEO
Founded CycloSyn to develop next-generation cyclodextrin nanosystems. Leads company vision, platform strategy, and BD positioning.
KK
Kylah C. Koch, PhD
Chief Scientific Advisor
PhD in Polymer Science & Engineering. Leads scientific development, formulation design, and experimental protocols for the β-CDP platform.
CE
Chathurani Ekanayake
R&D Scientist
PhD candidate in Chemistry (Kent State). Expert in cell-based assays, RT-qPCR, Western blotting, ELISA, and cancer-related signaling.
AW
Anthony Weilbruda
Formulation Chemist
Formulation chemist with experience in lipid nanoparticle drug delivery systems. Supports synthesis and preparation of cyclodextrin nanosystems.

Work With Us

Ready to advance
drug delivery?

We collaborate with pharmaceutical, biotech, and academic groups on joint development, licensing, and strategic investment. Let's talk.

Schedule a Call → Request a Technical Brief